SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29–June 2, 2026, in Chicago. Two breast cancer abstracts demonstrate the performance of Artera’s MMAI across clinically challenging settings. One study assesses prognosis and chemotherapy benefit stratification in node‐positive HR+ breast cancer